Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$41.78-0.17%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
3.09 → 3.11 EPS · FY ending Dec 31, 2027 · 10 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 10; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for TEVA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve free cash flow of $2.0-$2.4 billion in FY26 | Free cash flow is targeted at $2.0-$2.4 billion. | Intact | Free cash flow falls below $2.0 billion in FY26 | Free cash flow: $307M FY2026-Q2; GAAP. Published target: >= $2.0 billion. Annual target cannot be compared with a quarterly or TTM observation. Jul 29, 2026307,000,000 USD · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a growth-transition thesis, built on shifting the business toward innovative brands while sustaining its biosimilars portfolio. The thesis is intact, with recent financial performance in the top half of its industry and stated priorities on track.
The evidence describes TEVA as expensive, despite a peer comparison that points to a cheaper valuation; confidence in that comparison is low. Expectations are not fully aligned with the positive outlook in the evidence, but the gap is not a reliable valuation signal on its own.
Near term, management has raised its 2026 outlook for key innovative brands, which grew strongly in the first half, and is advancing late-stage pipeline programs. Biosimilars are on track toward a stated 2027 revenue goal, but the industry has a high rate of earnings misses and TEVA’s recent surprises have been erratic.
Over the next one to three years, the thesis depends on continued growth in innovative brands, progress in late-stage programs, and delivery on biosimilars. A reversal and guidance cut after the recent raise would damage credibility; weaker employment data could also raise recession concerns, while continued strength from Healthcare peers would support the sector backdrop.
The multi-year view is intact, supported by execution in growth priorities, but the expensive valuation and need to sustain delivery leave meaningful execution risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Recent earnings beats show improving execution. |
| Broken |
| Earnings misses with guidance cuts in two consecutive quarters |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain operating margin near 26.6% in FY25 | A supporting condition in TEVA PHARMACEUTICAL INDUSTRIES LTD's published investment case. The stated target is ~26.65%. | Broken | Operating margin falls below 25% in FY25 | Operating margin: 16.25% FY2026-Q3; GAAP. Published target: ~26.65%. Annual target cannot be compared with a quarterly or TTM observation. Nov 3, 202616.245734 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain revenue between $16.4B and $16.8B in FY26 | A primary condition in TEVA PHARMACEUTICAL INDUSTRIES LTD's published investment case. The stated target is >= $16.4 billion. | Intact | Annual revenue falls below $16.4 billion in FY26 | Revenue: $4.395B FY2026-Q3; GAAP. Published target: >= $16.4 billion. Annual target cannot be compared with a quarterly or TTM observation. Nov 3, 20264,395,000,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$3.09 → $3.11 · observed estimates
$17.23B → $17.37B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $3.09 | $17,232,322,990 | 12 / 10 |
| 2026-07-25 | $3.09 | $17,232,322,990 | 12 / 10 |
| 2026-07-26 | $3.08 | $17,204,194,190 | 7 / 8 |
| 2026-07-27 | $3.09 | $17,232,322,990 | 12 / 10 |
| 2026-07-28 | $3.09 | $17,232,322,990 | 12 / 10 |
| 2026-07-29 | $3.09 | $17,197,376,340 | 7 / 8 |
| 2026-07-30 | $3.08 | $17,238,533,519 | 7 / 8 |
| 2026-07-31 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-01 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-02 | $3.07 | $17,304,303,700 | 12 / 10 |
| 2026-08-03 | $3.07 | $17,304,303,700 | 12 / 10 |
| 2026-08-04 | $3.07 | $17,304,303,700 | 12 / 10 |
| 2026-08-05 | $3.07 | $17,304,303,700 | 12 / 10 |
| 2026-08-06 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-08 | $3.07 | $17,304,303,700 | 12 / 10 |
| 2026-08-09 | $3.07 | $17,304,303,700 | 12 / 10 |
| 2026-08-10 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-12 | $3.07 | $17,304,303,700 | 12 / 10 |
| 2026-08-13 | $3.07 | $17,304,303,700 | 12 / 10 |
| 2026-08-14 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-15 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-16 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-17 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-18 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-19 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-20 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-21 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-22 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-23 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-24 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-25 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-26 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-27 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-28 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-29 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-30 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-08-31 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-09-01 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-09-02 | $3.07 | $17,285,479,256 | 7 / 8 |
| 2026-09-03 | $3.06 | $17,286,308,699 | 7 / 8 |
| 2026-09-04 | $3.06 | $17,286,304,713 | 7 / 8 |
| 2026-09-05 | $3.07 | $17,285,100,204 | 7 / 8 |
| 2026-09-06 | $3.07 | $17,285,100,204 | 7 / 8 |
| 2026-09-07 | $3.07 | $17,285,100,204 | 7 / 8 |
| 2026-09-08 | $3.07 | $17,285,100,204 | 7 / 8 |
| 2026-09-09 | $3.07 | $17,285,100,204 | 7 / 8 |
| 2026-09-10 | $3.07 | $17,285,100,204 | 7 / 8 |
| 2026-09-11 | $3.06 | $17,305,750,178 | 7 / 8 |
| 2026-09-12 | $3.06 | $17,305,750,178 | 7 / 8 |
| 2026-09-13 | $3.06 | $17,305,750,178 | 7 / 8 |
| 2026-09-14 | $3.06 | $17,305,750,178 | 7 / 8 |
| 2026-09-15 | $3.05 | $17,253,756,475 | 7 / 8 |
| 2026-09-16 | $3.05 | $17,248,754,404 | 6 / 7 |
| 2026-09-17 | $3.07 | $17,307,702,086 | 6 / 7 |
| 2026-09-18 | $3.07 | $17,307,702,086 | 6 / 7 |
| 2026-09-19 | $3.08 | $17,366,650,591 | 3 / 8 |
| 2026-09-20 | $3.08 | $17,366,650,591 | 4 / 8 |
| 2026-09-21 | $3.08 | $17,366,650,591 | 4 / 8 |
| 2026-09-22 | $3.07 | $17,355,934,734 | 4 / 8 |
| 2026-09-23 | $3.08 | $17,412,218,565 | 4 / 8 |
| 2026-09-24 | $3.10 | $17,459,609,081 | 4 / 8 |
| 2026-09-25 | $3.07 | $17,296,026,655 | 5 / 8 |
| 2026-09-26 | $3.06 | $17,254,476,219 | 4 / 9 |
| 2026-09-27 | $3.06 | $17,273,166,098 | 5 / 9 |
| 2026-09-28 | $3.06 | $17,273,166,098 | 5 / 9 |
| 2026-09-29 | $3.06 | $17,270,533,475 | 5 / 9 |
| 2026-09-30 | $3.04 | $17,125,192,220 | 5 / 9 |
| 2026-10-01 | $3.04 | $17,171,216,328 | 5 / 9 |
| 2026-10-02 | $3.05 | $17,193,331,556 | 5 / 9 |
| 2026-10-03 | $3.07 | $17,172,401,382 | 6 / 10 |
| 2026-10-04 | $3.07 | $17,168,126,965 | 6 / 10 |
| 2026-10-05 | $3.09 | $17,231,440,995 | 6 / 10 |
| 2026-10-06 | $3.09 | $17,231,440,995 | 6 / 10 |
| 2026-10-07 | $3.08 | $17,219,292,883 | 6 / 10 |
| 2026-10-08 | $3.10 | $17,329,742,859 | 6 / 10 |
| 2026-10-09 | $3.08 | $17,195,555,294 | 7 / 10 |
| 2026-10-10 | $3.08 | $17,227,809,945 | 8 / 10 |
| 2026-10-11 | $3.08 | $17,227,809,945 | 8 / 10 |
| 2026-10-12 | $3.08 | $17,206,825,960 | 8 / 10 |
| 2026-10-13 | $3.06 | $17,122,663,596 | 9 / 10 |
| 2026-10-14 | $3.06 | $17,130,045,191 | 9 / 10 |
| 2026-10-15 | $3.03 | $16,988,213,120 | 9 / 10 |
| 2026-10-16 | $3.04 | $16,988,213,120 | 9 / 10 |
| 2026-10-17 | $3.04 | $16,988,213,120 | 9 / 10 |
| 2026-10-18 | $3.04 | $16,968,177,363 | 9 / 10 |
| 2026-10-19 | $3.04 | $16,968,177,363 | 9 / 10 |
| 2026-10-20 | $3.02 | $16,898,579,469 | 9 / 9 |
| 2026-10-21 | $3.04 | $16,985,731,138 | 9 / 9 |
| 2026-10-22 | $3.04 | $17,020,042,547 | 9 / 9 |
| 2026-10-23 | $3.06 | $17,093,859,778 | 8 / 9 |
| 2026-10-24 | $3.04 | $16,971,452,063 | 8 / 9 |
| 2026-10-25 | $3.04 | $16,971,452,063 | 8 / 9 |
| 2026-10-26 | $3.04 | $16,971,452,063 | 8 / 9 |
| 2026-10-27 | $3.04 | $16,971,452,063 | 8 / 9 |
| 2026-10-28 | $3.07 | $17,167,234,539 | 8 / 9 |
| 2026-10-29 | $3.09 | $17,279,205,882 | 8 / 9 |
| 2026-10-30 | $3.03 | $16,911,135,633 | 8 / 9 |
| 2026-10-31 | $3.04 | $16,976,538,164 | 8 / 9 |
| 2026-11-01 | $3.04 | $16,976,538,164 | 8 / 9 |
| 2026-11-02 | $3.04 | $16,976,538,164 | 8 / 9 |
| 2026-11-03 | $3.09 | $17,249,152,069 | 9 / 10 |
| 2026-11-04 | $3.11 | $17,367,858,011 | 10 / 11 |
| 2026-11-05 | $3.11 | $17,367,858,011 | 10 / 11 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 13 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 4 recorded
1 raises · 0 cuts · 0 unchanged · 2 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.